Prognostic role of serum total cholesterol and high-density lipoprotein cholesterol in cancer survivors: A systematic review and meta-analysis

Zhou, Pingting; Li, Bo; Liu, Bin; Chen, Tianrui

doi:10.1016/j.cca.2017.11.039

Cited by 82 publications

(86 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The serum albumin is well known to reflect nutritional status as well as systematic inflammatory response, and has been reported to be associated with prognosis in cancer (2,23). In addition, the total cholesterol level has been described to be related to cancer survival (24). The total lymphocyte count is known as an indicator reflecting the immunological and nutritional status, and is also reported to be associated with prognosis in EC patients (10,25).…”

Section: Discussionmentioning

confidence: 99%

Systematic Review on the Controlling Nutritional Status (CONUT) Score in Patients Undergoing Esophagectomy for Esophageal Cancer

et al. 2020

View full text Add to dashboard Cite

Background/Aim: The present study aimed to examine the association of the controlling nutritional status (CONUT) score with outcomes in patients undergoing esophagectomy for esophageal cancer (EC). Materials and Methods: A systematic literature review was carried out to investigate the impact of the CONUT score in EC. Next, metaanalysis of long-term outcomes was performed. Results: The search found six eligible retrospective studies, and five studies with 952 patients were included in the meta-analysis. Metaanalysis found a significant association of the CONUT score with outcomes including overall survival [hazard ratio (HR)=2.51, 95% confidence interval (CI)=1.75-3.60, p<0.001], cancer-specific survival (HR=2.60, 95%CI=1.53-4.41, p<0.001), and recurrence free survival (HR=2.08, 95%CI=1.39-3.12, p<0.001). Conclusion: The CONUT score may be an independent predictor associated with prognosis in patients undergoing esophagectomy for EC. However, further studies are needed to clarify the association of the CONUT score with postoperative outcomes in EC patients. Preoperative nutritional status has recently been highlighted as an important determinant to predict prognosis of cancer (1-3). The controlling nutritional status (CONUT) score is a newly developed system for nutritional screening, which is calculated by three laboratory values: plasma albumin, plasma cholesterol and total lymphocyte count (4). Recently, the association of the CONUT score with outcomes has been demonstrated in the field of surgical oncology (5-9). Since 2016, a few studies reported on the CONUT score in patients undergoing esophagectomy for esophageal cancer (EC) (10, 11). However, most studies included small sample sizes and the prognostic significance of the CONUT score in EC has not been systematically investigated so far. The aim of the present study was to perform a systematic review to summarize the current published evidence regarding the CONUT score in EC. In addition, metaanalyses were carried out to investigate the prognostic significance of the CONUT score in EC. Materials and Methods A systematic review. A systematic literature search was conducted on the 13 th of December 2019 and applied to five databases of Embase, Medline Ovid, Web of Science, Cochrane CENTRAL, and Google scholar, to find out all available articles on the CONUT score and the association with outcome in patients undergoing esophagectomy for EC. The search was limited in English articles with no restrictions on the publication year. This study reports in compliance with the Preferred Reporting Items for Systematic Reviewers and Meta-Analyses (PRISMA) guidelines (12), and is registered with the University Hospital Medical Information Network (UMIN000040112). First, duplicate records were removed. Next, all the title and abstracts were screened to determine the eligible studies. Finally, full-text articles were assessed to meet the inclusion criteria. The following data were extracted: study information (publication year, country of the study, and study design), pa...

show abstract

Section: Discussionmentioning

confidence: 99%

Systematic Review on the Controlling Nutritional Status (CONUT) Score in Patients Undergoing Esophagectomy for Esophageal Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A number of observational studies and retrospective study analyses have shown that plasma HDL-C and ApoA-I levels are significantly reduced in cancer patients, including those with breast, ovarian, colon, prostate, and pancreatic carcinomas ( 34 – 50 ). These studies are summarized in Table 1 .…”

Section: Hdl-c In Cancermentioning

confidence: 99%

HDL in Endocrine Carcinomas: Biomarker, Drug Carrier, and Potential Therapeutic

Morin

Schwendeman

2018

Front. Endocrinol.

View full text Add to dashboard Cite

High-density lipoprotein (HDL) have long been studied for their protective role against cardiovascular diseases, however recently relationship between HDL and cancer came into focus. Several epidemiological studies have shown an inverse correlation between HDL-cholesterol (HDL-C) and cancer risk, and some have even implied that HDL-C can be used as a predictive measure for survival prognosis in for specific sub-population of certain types of cancer. HDL itself is an endogenous nanoparticle capable of removing excess cholesterol from the periphery and returning it to the liver for excretion. One of the main receptors for HDL, scavenger receptor type B-I (SR-BI), is highly upregulated in endocrine cancers, notably due to the high demand for cholesterol by cancer cells. Thus, the potential to exploit administration of cholesterol-free reconstituted or synthetic HDL (sHDL) to deplete cholesterol in endocrine cancer cell and stunt their growth of use chemotherapeutic drug loaded sHDL to target payload delivery to cancer cell has become increasingly attractive. This review focuses on the role of HDL and HDL-C in cancer and application of sHDLs as endocrine cancer therapeutics.

show abstract

“…Previous studies have investigated the correlations between serum lipid levels and human cancers [ 9 , 10 ]. Serum cholesterol, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were shown to be associated with the prognosis in multiple human cancers, such as colorectal cancer, liver cancer, and breast cancer [ 11 – 13 ]. As the major protein component of plasma HDL, apolipoprotein A-I (ApoA-I) synthesized in the liver and small intestine has been reported to be associated with clinical survival in multiple human cancers, including gastric cancer, nasopharyngeal carcinoma, and breast cancer [ 14 – 17 ].…”

Section: Introductionmentioning

confidence: 99%

Prognostic Significance of Pretreatment Apolipoprotein A-I as a Noninvasive Biomarker in Cancer Survivors: A Meta-Analysis

Zhang

Yang

2018

Disease Markers

View full text Add to dashboard Cite

Background Numerous studies have reported the prognostic significance of serum apolipoprotein A-I (ApoA-I) in various cancers, but the results have been inconsistent. The current meta-analysis was performed to investigate the association between ApoA-I level and prognosis in human malignancies. Methods A literature search was performed using the electronic platforms of the PubMed, Cochrane Library, Web of Science, Embase, Wanfang, and China National Knowledge Infrastructure (CNKI) databases to obtain eligible articles published up to May 20, 2018. Pooled hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated to assess the prognostic values of the ApoA-I level in cancers using STATA 12.0 software. Results A total of 14 studies involving 9295 patients were included. The results indicated that low ApoA-I level was significantly associated with poor overall survival (OS) (HR = 0.52, 95% CI: 0.44–0.61). Significant relationships between the ApoA-I level and OS were specifically detected in nasopharyngeal carcinoma (NPC, HR = 0.63, 95% CI: 0.54–0.73), colorectal cancer (CRC, HR = 0.48, 95% CI: 0.19–0.76), and hepatocellular carcinoma (HCC, HR = 0.46, 95% CI: 0.27–0.65). The subgroup analyses for OS also further confirmed the prognostic significance of the ApoA-I level in cancers. Moreover, lower Apo A-I was associated with unfavorable cancer-specific survival (CSS, HR: 0.47, 95% CI: 0.19–0.76) in cancers, and low ApoA-I level was clearly associated with inferior total time to recurrence (TTR, HR: 0.43, 95% CI: 0.29–0.58) in HCC, poorer locoregional recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) (HR: 0.58, 95% CI: 0.42–0.74 for LRFS; HR: 0.65, 95% CI: 0.41–0.89 for DMFS) in NPC, and shorter disease-free survival (DFS, HR: 0.64, 95% CI: 0.43–0.84) in cancers. Conclusions. Low ApoA-I level might be an unfavorable prognostic factor in multiple malignancies, and serum ApoA-I could serve as a noninvasive marker to predict cancer prognosis.

show abstract

Prognostic role of serum total cholesterol and high-density lipoprotein cholesterol in cancer survivors: A systematic review and meta-analysis

Cited by 82 publications

References 78 publications

Systematic Review on the Controlling Nutritional Status (CONUT) Score in Patients Undergoing Esophagectomy for Esophageal Cancer

Systematic Review on the Controlling Nutritional Status (CONUT) Score in Patients Undergoing Esophagectomy for Esophageal Cancer

HDL in Endocrine Carcinomas: Biomarker, Drug Carrier, and Potential Therapeutic

Prognostic Significance of Pretreatment Apolipoprotein A-I as a Noninvasive Biomarker in Cancer Survivors: A Meta-Analysis

Contact Info

Product

Resources

About